Seqirus, the second-largest manufacturer of flu vaccine in the world, plans to expand production at its Holly Springs plant.
The company recently announced the U.S. Food & Drug Administration had approved its next-generation cell-based manufacturing process, which will enable Seqirus to more than double vaccine production for the 2019-20 flu season.
Seqirus has already gone from 3 million doses of vaccine a few years ago to more than 20 million this year.
“With the recent approval of our new innovative process, that’s going to double to 40 million doses by next year,” said Brent MacGregor, vice president for commercial operations. “We’re not going to stop there. We’re going to continue to increase production out of this facility.”
Using cell-based manufacturing is not only faster, it’s more consistent, MacGregor said.
Seqirus employs about 600 people at the Holly Springs plant.